Avalo Therapeutics (AVTX)

• Market cap: $51.4M
• 1 day: -2.45%
• 5 days: -2.65%
• 1 month: 1.49%
• 3 months: -2.45%
• 6 months: -30.42%
• Year to date: -43.30%
• 1 year: -60.17%
• 5 years: -99.93%
• 10 years: -99.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).

Employees: 23

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

175% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 4

25% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 4

18% more capital invested

Capital invested by funds: $56M [Q4 2024] → $66.1M (+$10.2M) [Q1 2025]

5.37% more ownership

Funds ownership: 71.99% [Q4 2024] → 77.37% (+5.37%) [Q1 2025]

3% more funds holding

Funds holding: 33 [Q4 2024] → 34 (+1) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $15 214% upside
• Avg. target: $15 214% upside
• High target: $15 214% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Mitchell Kapoor

214% upside $15

Buy Assumed

2 Jun 2025